Many breast cancer survivors experience long-term adverse effects of adjuvant systemic therapy, including cognitive decline. The decline of cognitive functions can have a detrimental impact on quality of life and might interfere with independent living. This Review discusses the tissue-selective side effects of endocrine therapies and specifically their impact on cognitive function. The critical issues that need to be addressed to best assess the cognitive effects of endocrine treatment in patients with breast cancer are highlighted.
- Wilbert Zwart
- Huub Terra
- Sanne B. Schagen
